myeloma


Also found in: Dictionary, Thesaurus, Encyclopedia, Wikipedia.
Related to myeloma: multiple myeloma

myeloma

 [mi″ĕ-lo´mah]
1. a tumor composed of plasma cells of the type normally found in the bone marrow.
giant cell myeloma giant cell tumor (def. 1).
multiple myeloma see multiple myeloma.
plasma cell myeloma multiple myeloma.
solitary myeloma a variant of multiple myeloma in which there is a single localized tumor focus. Called also plasma cell tumor.

my·e·lo·ma

(mī'ĕ-lō'mă),
1. A tumor composed of cells derived from hemopoietic tissues of the bone marrow.
2. A plasma cell tumor.
[myelo- + G. -oma, tumor]

myeloma

(mī′ə-lō′mə)
n. pl. myelo·mas or myelo·mata (-mə-tə)
A malignant tumor formed by the cells of the bone marrow.

my′e·lo′ma·toid′ (-toid′) adj.

myeloma

Malignant plasmacytoma, multiple myeloma, multiple plasmacytoma of bone, myelomatosis, plasma cell myeloma Hematology A neoplastic proliferation of plasma cells in BM and extramedullary sites; if circumscribed, plasmacytoma Epidemiology MM comprises 10% of hematopoietic malignancies, causing 10,000 deaths/yr–US; ↑ with age; black:white 2:1 Clinical As the myeloma cells proliferate in BM, they cause osteolysis, resulting in pathologic fractures and industrial strength pain, anorexia, nausea, thirst, fatigue, muscle weakness, restlessness, confusion; BM replacement by neoplastic plasma cells results in ↑ infections and anemia due to displacement of normal WBCs, and erythroid series; excess Igs in circulation plug up renal tubules Lab Monoclonal Igs, often light chains, in serum, urine; ↑ Ca2+; normal PO4, normal alk phos Complications Painful pathologic fractures, anemia, hypercalcemia, renal failure, recurrent bacterial infections Treatment 1º chemotherapy: Melphalan and prednisone; VAD–vincristine, Adriamycin, dexamethasone in new cases; IFN-α has been used for maintenance; myeloablative therapy, allogeneic BMT from HLA-matched siblings. See Clear cell, myeloma, Indolent myeloma, Myeloma kidney, Solitary myeloma.

my·e·lo·ma

(mī'ĕ-lō'mă)
1. A tumor composed of cells derived from hemopoietic tissues of the bone marrow.
2. A plasma cell tumor.
[myelo- + G. -oma, tumor]

myeloma

A tumour derived from a lymphocyte. See LYMPHOMA, MYELOMATOSIS.

myeloma

a cancerous tumour of the bone marrow.

Myeloma

A tumor that originates in bone marrow and usually spreads to more than one bone.

my·e·lo·ma

(mī'ĕ-lō'mă)
1. A tumor composed of cells derived from hemopoietic tissues of bone marrow.
2. A plasma cell tumor.
[myelo- + G. -oma, tumor]

Patient discussion about myeloma

Q. Multiple Myeloma what and how is it treated and what is MGUF

A. Were you referring by any chance to MGUS (monoclonal gammopathy of unknown significance)? It's a condition that resembles myeloma but is much more widespread and by itself isn't considered malignant. It may, however, deteriorate to multiple myeloma over the years.

Myeloma is treated with chemotherapy of various kinds, and sometimes with bone marrow transplantation with the patients own bone marrow.

You may read more here:
www.nlm.nih.gov/medlineplus/multiplemyeloma.html

More discussions about myeloma
References in periodicals archive ?
The approval is based on data from the Phase III ALCYONE study that showed a reduction of the risk of disease progression or death by 50 percent in newly diagnosed ASCT ineligible multiple myeloma patients when daratumumab is combined with bortezomib, melphalan and prednisone.
Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients.
Food and Drug Administration had already approved selinexor in early July to treat patients with multiple myeloma resistant to multiple therapies.
The company's randomised, open-label, multicenter Phase 3 COLUMBA study included 522 patients with multiple myeloma, who had received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD), or whose disease was refractory to both a PI and an IMiD.
"The approval of these combination therapies marks a significant milestone for patients with multiple myeloma in Europe," said Nadim Ahmed, President of Hematology/Oncology for Celgene.
Susan Henry, an administrator for cancer services, told an auditor that she felt that Morgan and his predecessor as director of the Myeloma Center, Dr.
It is conceivable that emerging mutational and molecular information may be incorporated into the future risk stratification and prognostication of myeloma patients.
Further evaluation of the myeloma revealed a monoclonal IgG lambda of 7600 mg/dL and a kappa/lambda ratio of 0.01.
Assessment of bone marrow plasma cell infiltrates in multiple myeloma: the added value of CD138 immunohistochemistry.
Amgen's sBLA for XGEVA (denosumab) to expand the currently approved indication for the prevention of skeletal-related events in patients with bone metastases from solid tumors, has been approved to include multiple myeloma. The approval is based on data from the pivotal Phase III '482 study, the largest international multiple myeloma clinical trial ever conducted, which enrolled 1,718 patients.
Multiple myeloma is diagnosed using blood or urine samples which help in finding abnormal antibodies.